Company intelligence / Profile preview
GeneSys Biologics
Hyderabad, Telangana, Indiagenesysbiologics.com ↗
- Ownership
- Private
- Employees
- ~213
- Development stage
- Commercial
01
Overview
GeneSys Biologics has developed multiple insulin biosimilar candidates. Its lead product, Glargine, completed Phase I in India and was in Phase III as of late 2022; trials were expected to complete by February 2024 with commercial operations targeted for June 2024. The company has also completed preclinical toxicology studies for four products[4].
- Therapeutic areas
- Endocrinology
- Modalities
- Biosimilars (notably insulin biosimilars)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
CIVICA Rx – co-development and commercialization agreement for three insulins (Glargine, Lispro, Aspart)[4].
Beyond the preview
Go deeper on GeneSys Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeneSys Biologics.